Moleculin Biotech Inc (MBRX): Moleculin Regains Compliance with NASDAQ...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	55
Posts	13535
Boards Moderated	0
Alias Born	10/12/2006

king oil

Re: None

Thursday, 07/13/2017 8:37:43 AM

Thursday, July 13, 2017 8:37:43 AM

Moleculin Regains Compliance with NASDAQ Listing Requirements

HOUSTON, TX -- (Marketwired) -- 07/12/17 -- Moleculin Biotech, Inc. (MBRX), (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 6, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Moleculin is in compliance with the minimum bid price requirement and NASDAQ considers the matter closed.